Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluated the influence of some single nucleotide polymorphisms (SNPs) on these pharmacokinetic data after 1 month of triple therapy in humans.
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir
CUSATO, JESSICA
First
;ALLEGRA, SARAH;DE NICOLO', AMEDEO;BOGLIONE, Lucio;FATIGUSO, GIOVANNA;DI PERRI, Giovanni;D'AVOLIO, ANTONIOLast
2015-01-01
Abstract
Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluated the influence of some single nucleotide polymorphisms (SNPs) on these pharmacokinetic data after 1 month of triple therapy in humans.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
37 24080-61765-1-PB.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
253.02 kB
Formato
Adobe PDF
|
253.02 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
